Breaking News

Financial Report: Alexion

April 24, 2014

Solaris revenue up 67% in the quarter

Alexion
 
1Q Revenues: $566.6 million (+67%)

1Q Earnings: $159.4 million (+94%)

Comments: Solaris sales were $566.6 million, up 67%, which included $87.8 million in reimbursements of prior year shipments related to an agreement with the French government. Sales also include additions of new patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). R&D expenses were $191.5 million, up from $74.5 in 1Q13.
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks